TAKE A LOOK AT WHICH REPORT YOUR PORTFOLIO'S BEEN MISSING...

Shareholders Foundation offers real-time reporting of class action exposure on a per transaction basis,
including the documents you will need for claim filing and settlement recovery.
Start Monitoring Your Investments

Northfield Laboratories, Inc. Shareholder Class Action

  • You must submit the settlement Proof form attached below, in order to participate in this settlement. There is a strict deadline of May 1, 2012 by which all claims must be submitted. The instructions for submitting are included in the Proof and the Notice files attached below for your download. DO NOT SEND THE FORMS TO THE SHAREHOLDE

  • To have your information reviewed for options and to receive notifications about this case, please send an email to mail@shareholdersfoundation.com, or call us at (858) 779-1554.

Lawsuit Overview

Company
Northfield Laboratories, Inc.
Security
NASDAQ: NFLD

Case Name
Northfield Laboratories Shareholder Class Action 05/18/2010
Type of Lawsuit
Shareholder Class Action
Court of Filing
U.S. District Court for the Northern District of Illinois

Class Period Begin
Class Period End
Settlement Notice
Northfield_Laboratories_Notice_2012.pdf
Settlement Proof
Northfield_Laboratories_Proof_2012.pdf
You must register or login to receive notifications.

Click here to subscribe to Northfield Laboratories, Inc..

Settlement Overview

Date Settled
Date Settled
Settlement Amount
$1,500,000.00
Deadline to Participate in Settlement

You must register to view and download the Settlement Notice and Settlement Proof.

Summary

According to the Notice:
If approved by the Court, the settlement will provide $1,500,000, plus interest (the Settlement Amount ), to pay claims of investors who purchased Northfield Stock during the period from August 16, 2004 through and including March 2, 2006 (the Class Period ).

The Settlement represents an average recovery of $0.054 per share of Northfield Stock for the 27.770 million shares outstanding as of March 2006, the end of the Class Period. A share may have been traded more than once during the Class Period. This estimate solely reflects the average recovery per outstanding share if Northfield Stock. The indicated average recovery per share will be the total average recovery for all purchasers of that share. This is not an estimate of the actual recovery per share you should expect. Your actual recovery will depend on the aggregate losses of all Class Members, the date(s) you purchased and sold Northfield Stock, and the total number and amount of claims filed.

The Settlement resolves the lawsuit concerning whether Northfield and its officers and directors made false and misleading statements, in violation of federal securities laws, based upon the allegations set forth in the Consolidated Second amended Complaint, including that : (1) Northfield allegedly concealed that it had terminated or closed its October 2000 trial of Acute Normovelemic Hemodilution for Northfield's blood-substitute PolyHeme because of adverse effects; and (2) Northfield allegedly knew or should have known that use of PolyHeme had adverse effects; and (3) Northfield allegedly concealed that use of PolyHeme had adverse effects. Defendants Northfield, Steven A. Gould, M.D. ( Gould ), and Richard E. DeWoskin ( DeWoskin ) deny all allegations of misconduct.

Date Settled